Abstracts tagged "patient-reported outcome measures"

Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 433 • 2019 ACR/ARP Annual Meeting
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Ruchi Patel ¹, Valeria Esparza ², Jin-Shei Lai ¹, Elizabeth Gray ¹, Rowland Chang ³, David Cella ³ and Kaveh Ardalan⁴, ¹Northwestern University Feinberg School of Medicine, Chicago, ²University of Illinois-Chicago College of Medicine, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…
Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Joe Zhuo ⁷, Kuan-Hsiang Gary Huang ⁸, Robert Wong ⁷, Sean Connolly ⁸, Yedid Elbez ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Excelya, Boulogne-Billancourt, France, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…
Abstract Number: 435 • 2019 ACR/ARP Annual Meeting
Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
W. Benjamin Nowell¹, Carol Gaich ², Kelly Gavigan ¹, Zhihong Cai ², Anabela Cardoso ², Theresa Hunter ³, Julie Birt ², Jennifer Workman ² and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patient-reported outcomes (PROs) are important indicators of treatment effectiveness and their role is increasing in comparative effectiveness studies. Little is known about PRO measures…
Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting
Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome
Eun Hye Park¹, You-Jung Ha ¹, Eun Ha Kang ¹, Yeong-Wook Song ² and Yun Jong Lee ³, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea
Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
Abstract Number: 441 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
Rosa Morlà¹, R. Castellanos ², Virginia Ruiz-Esquide ³, Julio Ramirez ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁵, Mariam Riad ⁶, Isabel Castrejon ⁶ and Theodore Pincus ⁶, ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Associations of depression with clinical status in RA1 and differences in clinical status in different countries2 have been reported. We compared MDHAQ (multidimensional health…
Abstract Number: 1508 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Lianne Gensler ¹, Jonathan Kay ², Walter P. Maksymowych ³, Nigil Haroon ⁴, Lars Bauer ⁵, Bengt Hoepken ⁵, Natasha de Peyrecave ⁶, Thomas Kumke ⁷ and Atul Deodhar⁸, ¹University San Francisco California, San Francisco, CA, ²UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Pain, fatigue, morning stiffness and impaired sleep are some of the main symptoms contributing to reduced quality of life (QoL) in patients (pts) with…
Abstract Number: 442 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care
Rosa Morlà¹, Mariam Riad ², Virginia Ruiz-Esquide ³, Fernando Espi ⁴, Julio Ramirez ⁵, Nuria Del Castillo ⁶, Jose Gomez-Puerta ⁷, Raimon Sanmarti ⁷, Theodore Pincus ² and Isabel Castrejon ², ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Rush University Medical Center, Chicago, IL, ⁵Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁶Xarxa Social i Sanitaria de Santa Tecla, Tarragona, Spain, ⁷Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) are more likely to report depression than the general population, and depression has been associated with…
Abstract Number: 1537 • 2019 ACR/ARP Annual Meeting
Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
Stefan Siebert¹, Elisa Gremese ², Paul Bergmans ³, Kurt De Vlam ⁴, Beatriz Joven-Ibáñez ⁵, Gkikas Katsifis ⁶, Tatiana Korotaeva ⁷, Wim Noël ⁸, Carlo Selmi ⁹, Petros Sfikakis ¹⁰, Pavel Smirnov ¹¹, Elke Theander ¹², Michael Nurmohamed ¹³, Laure Gossec ¹⁴ and Josef Smolen ¹⁵, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ⁹Humanitas Research Hospital, University of Milan, Milan, Italy, ¹⁰Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹¹Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹²Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹³Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹⁴Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: The additional benefit of methotrexate as a concomitant treatment in PsA has not been fully elucidated. Observational data exist for concomitant methotrexate (MTX) use…
Abstract Number: 453 • 2019 ACR/ARP Annual Meeting
Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status
Sofia Pazmino¹, Anikó Lovik ², Annelies Boonen ³, Diederik De Cock ¹, Veerle Stouten ¹, Johan Joly ⁴, Kristien Van der Elst ⁵, Delphine Bertrand ¹, Rene Westhovens ⁶ and Patrick Verschueren ⁵, ¹KU Leuven, Leuven, Belgium, ²Leuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Leuven, Vlaams-Brabant, Belgium, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁵University Hospital Leuven, Leuven, Belgium, ⁶University Hospitals, Leuven, Belgium
Background/Purpose: Rheumatoid arthritis (RA) level of disease activity, cannot be evaluated by a single clinical or laboratory measurement. Hence, composite indices have been created via…
Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 648 • 2019 ACR/ARP Annual Meeting
Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity
Katie Zuech¹, Ly Tran ², Teresa Aberle ¹, Cristina Arriens ³, Eliza F. Chakravarty ³, Joan T. Merrill ⁴ and Judith James ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus (SLE) may have a significant impact on multiple dimensions of quality of life. Patient-reported outcome (PRO) tools may provide valuable insights for…
Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting
Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Gaëlle Chédeville¹, Michelle Batthish ², Roberta Berard ³, Roxana Bolaria ⁴, Alessandra Bruns ⁵, David Cabral ⁶, Ciaran Duffy ⁷, Kerstin Gerhold ⁸, Tommy Gerschman ⁶, Jean-Philippe Proulx-Gauthier ⁹, Alan Rosenberg ¹⁰, Dax Rumsey ¹¹, Heinrike Schmeling ¹², Natalie Shiff ¹³, Gordon Soon ¹⁴, Lori Tucker ¹⁵ and Jaime Guzman ⁶, ¹The Montreal Children's Hospital, McGill University, Montreal, Canada, ²McMaster University, Hamilton, Canada, ³Children's Hospital, London Health Sciences Centre, London, Canada, ⁴University of British Columbia, Victoria, BC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université Laval, Québec, QC, Canada, ¹⁰University of Saskatchewan, Saskatoon, SK, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹³University of Florida, Gainesville, FL, ¹⁴University of Toronto, Toronto, ON, Canada, ¹⁵British Columbia Children’s Hospital, Vancouver, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…
Abstract Number: 833 • 2019 ACR/ARP Annual Meeting
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Yvonne Lee¹, Fengxin Lu ², Joshua Colls ², Meredith Murray ², Dong Suh ², Jing Song ³, Julia (Jungwha) Lee ⁴, Dorothy Dunlop ⁴ and Daniel Solomon ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, ²Brigham and Women's Hospital, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Treat to target (TTT) is an effective strategy to improve outcomes in rheumatoid arthritis (RA). However, barriers to TTT include frequent clinic visits, poor…
Abstract Number: 2513 • 2019 ACR/ARP Annual Meeting
Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Laura Coates¹, Andrew Bushmakin ², Oliver FitzGerald ³, Dafna Gladman ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Philip Helliwell ⁷, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³University College Dublin, Dublin, Ireland, ⁴University of Toronto, Toronto, ON, Canada, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.